ClinicalTrials.gg
RecruitingNCT03375619Updated Nov 17, 2026

Long-term Follow-up Study of Patients Receiving CAR-T Cells

An observational study in Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell and Lymphoma, Small Lymphocytic, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Medical College of Wisconsin · Observational

From the registry’s dates

  • Started Dec 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Planned enrollment
26th of 91
500 · median 135
Started
2017
with 38 others
Observational
91 of 1,501
25 open now
Primary completion
2035-01
later than 240 of 248 live
Registered
1,183rd of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 26th largest by planned enrollment of the 91 observational ones that give a count, is one of 39 that started in 2017, is one of 91 observational ones, reaches primary completion later than 240 of the 248 other live ones, and was the 1,183rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

133 more — sign in →

All 138 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following:

Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Read the detailed description

The objective is to follow participants receiving CAR-T cells from years 2 to 15 post-treatment for persistence of CAR-T cells, development of secondary malignancies, or other medical complications.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Lymphomas Non-Hodgkin's B-Cell
  • Lymphoma, Small Lymphocytic
  • Mantle Cell Lymphoma
  • Central Nervous System Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Burkitt Lymphoma
  • Multiple Myeloma

Keywords

  • CAR-T Cell Therapy
  • chimeric antigen receptor
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria for this study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants who received CAR-T cells.

    Participants who received CAR-T cells at Froedtert Hospital \& the Medical College of Wisconsin in clinical trials (e.g., NCT05976555, NCT05094206, NCT05990465, NCT03019055 or NCT04186520).

    Other: Long-Term Follow-Up of Participants who Received CAR-T cells

Interventions

  • OtherLong-Term Follow-Up of Participants who Received CAR-T cells

    No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the incidence of a new malignancy at 5 years.

    The number of subjects with new malignancy.

    Time frame: Baseline to five years.

  2. Change from baseline in the incidence of a new malignancy at 10 years.

    The number of subjects with new malignancy.

    Time frame: Baseline to 10 years.

  3. Change from baseline in the incidence of a new malignancy at 15 years.

    The number of subjects with new malignancy.

    Time frame: Baseline to 15 years.

07

Study locations

1 of 1 sites recruiting
  • Froedtert Hospital & Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Cancer Center Clinical Trials Office · Contactcccto@mcw.edu · 414-805-8900
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Jan 2035, 205 months after the start.

Of 70 non-industry observational studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 30. This study's planned 205 months is above that.

Counting every sponsor, half of 104 studies reached it within 60 months; a quarter within 32 and three quarters within 176.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2017
First posted
Dec 18, 2017
StartActual
Dec 1, 2017
Primary completionEst.
Jan 1, 2035
CompletionEst.
Jan 1, 2035
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03375619
Responsible party
Nirav Shah (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Dec 18, 2017
Start date
Dec 1, 2017
Primary completion
Jan 1, 2035 (estimated)
Completion
Jan 1, 2035 (estimated)
Last update
Nov 17, 2026

Study contacts

Medical College of Wisconsin Clinical Cancer Center
Contact
cccto@mcw.edu
414-805-8900
Nirav Shah
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion